These results indicate that binding to MHC-II may be dispensable for the functions of LAG3 and suggests other ligands may exist, especially in the context of the role of LAG3 on CD8+ tumor-infiltrating lymphocytes (TILs). This evidence concerns the gene LAG3 and neoplasm.